quinoxalines has been researched along with azathioprine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allorge, D; Broly, F; Colombel, JF; Cortot, A; Jouet, JP; Torres, J; Tremblay, L | 1 |
| Barkema, HW; Clement, F; Coward, S; Ghosh, S; Heitman, SJ; Kaplan, GG; Leung, YP; Negron, M; Panaccione, R; Seow, C | 1 |
2 other study(ies) available for quinoxalines and azathioprine
| Article | Year |
|---|---|
Thiopurine S-methyltransferase deficiency associated with a novel mutation.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Benzazepines; Crohn Disease; Heterozygote; Humans; Male; Mesalamine; Methyltransferases; Mutation; Neutrophils; Nicotinic Agonists; Prednisolone; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2010 |
Funding a smoking cessation program for Crohn's disease: an economic evaluation.
Topics: Adult; Azathioprine; Benzazepines; Canada; Cost-Benefit Analysis; Crohn Disease; Directive Counseling; Female; Humans; Immunosuppressive Agents; Male; Models, Statistical; Nicotinic Agonists; Program Evaluation; Quality-Adjusted Life Years; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Tumor Necrosis Factor-alpha; Varenicline | 2015 |